AU5913198A - A method and composition for cancer treatment by enzymatic conversion of solubleradioactive toxic agents - Google Patents

A method and composition for cancer treatment by enzymatic conversion of solubleradioactive toxic agents

Info

Publication number
AU5913198A
AU5913198A AU59131/98A AU5913198A AU5913198A AU 5913198 A AU5913198 A AU 5913198A AU 59131/98 A AU59131/98 A AU 59131/98A AU 5913198 A AU5913198 A AU 5913198A AU 5913198 A AU5913198 A AU 5913198A
Authority
AU
Australia
Prior art keywords
solubleradioactive
composition
cancer treatment
enzymatic conversion
toxic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU59131/98A
Other languages
English (en)
Inventor
Samuel Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU5913198A publication Critical patent/AU5913198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU59131/98A 1997-01-13 1998-01-13 A method and composition for cancer treatment by enzymatic conversion of solubleradioactive toxic agents Abandoned AU5913198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/782,219 US6080383A (en) 1997-01-13 1997-01-13 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US08782219 1997-01-13
PCT/US1998/000511 WO1998030247A1 (en) 1997-01-13 1998-01-13 A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents

Publications (1)

Publication Number Publication Date
AU5913198A true AU5913198A (en) 1998-08-03

Family

ID=25125383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU59131/98A Abandoned AU5913198A (en) 1997-01-13 1998-01-13 A method and composition for cancer treatment by enzymatic conversion of solubleradioactive toxic agents

Country Status (5)

Country Link
US (2) US6080383A (enExample)
EP (1) EP1047456A4 (enExample)
JP (1) JP2001524941A (enExample)
AU (1) AU5913198A (enExample)
WO (1) WO1998030247A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807136B2 (en) * 1997-01-13 2010-10-05 David S. Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
US20030068382A1 (en) * 1999-05-18 2003-04-10 Samuel Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
CA2322969A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6565537B2 (en) * 2001-04-18 2003-05-20 Dennis R. Tollini Tube securing assembly
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030190350A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7615221B2 (en) * 2004-07-23 2009-11-10 Oncologic, Inc. Compositions and methods for treating cancer
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189470A (en) * 1973-01-30 1980-02-19 Bio-Response, Inc. Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans
US3964467A (en) * 1973-01-30 1976-06-22 Bio Response Inc. Methods and apparatus for augmentation of the production of anti-bodies in animals and humans and the collection thereof
CA1041445A (en) * 1973-04-09 1978-10-31 Sam Rose Method and apparatus for continuous mass in vitro suspension culture of cells
EP0109861A3 (en) * 1982-11-23 1986-05-14 Bio-Response Inc. Method for isolating cells
IN165717B (enExample) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
US6468503B2 (en) 2002-10-22
US6080383A (en) 2000-06-27
EP1047456A1 (en) 2000-11-02
WO1998030247A1 (en) 1998-07-16
JP2001524941A (ja) 2001-12-04
EP1047456A4 (en) 2004-06-16
US20020022003A1 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
AU5913198A (en) A method and composition for cancer treatment by enzymatic conversion of solubleradioactive toxic agents
AU6578998A (en) Method of treatment of migraine
AU9028798A (en) Method of improving drug treatment
AU7582398A (en) Composition for treating skin conditions
AU4063600A (en) A method of treating cancer
AU9016898A (en) Methods and compositions for treatment of restenosis
AU4981199A (en) Compositions and methods for modulating sexual activity
AU1775299A (en) Plant galactose dehydrogenase
AU3987700A (en) Application method of sealing agent
AU1562699A (en) Treatment of phosphating waste water
AU4546096A (en) Treatment of waste
AU2337997A (en) Method of treating cancer using c-26 modified bryostatin
AU1289699A (en) Method for treatment of metal substrates using mannich-derived polyethers
AU6256499A (en) A method of treating cancer
AUPQ199999A0 (en) A method of treatment and agents useful for same
AU781936C (en) A method of treatment and agents useful for same
AU4253999A (en) Composition and method for treatment of (pseudomonas)
AU9043098A (en) Plant and seed treatment method and composition therefor
AUPO826197A0 (en) Antinematodal soil treatment method and compositions therefor
AU6162499A (en) A method of treating cancer
AUPP045397A0 (en) Method of treatment
AUPO582097A0 (en) Method of treatment
AUPP110197A0 (en) Method of treatment
AUPO733797A0 (en) A method of treatment
AU2375297A (en) Treatment of hides